AYTU BIOPHARMA, INC. (AYTU) Gross margin 2017–2026
AYTU BIOPHARMA, INC. (AYTU) gross margin by fiscal year — reported gross profit divided by reported revenue.
64.0%FY2026 · since FY2017: 56.0% → 64.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | 64.0% | -5.1 pp |
| FY2025 | 69.0% | -6.2 pp |
| FY2024 | 75.3% | +13.2 pp |
| FY2023 | 62.0% | +8.0 pp |
| FY2022 | 54.1% | +9.6 pp |
| FY2021 | 44.5% | -25.5 pp |
| FY2020 | 70.0% | +0.1 pp |
| FY2019 | 69.9% | +25.9 pp |
| FY2018 | 44.0% | -12.0 pp |
| FY2017 | 56.0% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More AYTU financial trends
AYTU RevenueAYTU Net incomeAYTU Net marginAYTU Gross profitAYTU Operating incomeAYTU Operating marginAYTU Operating cash flowAYTU Free cash flowAYTU Capital expendituresAYTU Return on equityAYTU Stock buybacksAYTU Dividends paidAYTU Total assetsAYTU Total liabilitiesAYTU Shareholders’ equityAYTU overview →